User profiles for Raman Mahajan
 | Raman MahajanMédecins Sans Frontières / Doctors Without Borders Verified email at barcelona.msf.org Cited by 922 |
[HTML][HTML] Community-based management of severe acute malnutrition in India: new evidence from Bihar
Background: An estimated one-third of the world’s children who are wasted live in India. In
Bihar state, of children <5 y old, 27.1% are wasted and 8.3% have severe acute malnutrition (…
Bihar state, of children <5 y old, 27.1% are wasted and 8.3% have severe acute malnutrition (…
[HTML][HTML] Knowledge, attitudes, and practices related to antibiotic use in Paschim Bardhaman District: A survey of healthcare providers in West Bengal, India
M Nair, S Tripathi, S Mazumdar, R Mahajan… - PLoS …, 2019 - journals.plos.org
Introduction Antibiotic misuse is widespread and contributes to antibiotic resistance, especially
in less regulated health systems such as India. Although informal providers are involved …
in less regulated health systems such as India. Although informal providers are involved …
Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India
R Mahajan, P Das, P Isaakidis… - Clinical Infectious …, 2015 - academic.oup.com
Background. There are considerable numbers of patients coinfected with human immunodeficiency
virus (HIV) and visceral leishmaniasis (VL) in the VL-endemic areas of Bihar, India. …
virus (HIV) and visceral leishmaniasis (VL) in the VL-endemic areas of Bihar, India. …
Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India
Background. Reports on treatment outcomes of visceral leishmaniasis (VL)–human
immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied …
immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied …
[HTML][HTML] Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)
Background Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal
disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this …
disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this …
[HTML][HTML] “Without antibiotics, I cannot treat”: A qualitative study of antibiotic use in Paschim Bardhaman district of West Bengal, India
M Nair, S Tripathi, S Mazumdar, R Mahajan… - PloS one, 2019 - journals.plos.org
Background Misuse of antibiotics is a well-known driver of antibiotic resistance. Given the
decentralized model of the Indian health system and the shortage of allopathic doctors in rural …
decentralized model of the Indian health system and the shortage of allopathic doctors in rural …
[HTML][HTML] Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar …
Background A proportion of all immunocompetent patients treated for visceral leishmaniasis
(VL) are known to relapse; however, the risk factors for relapse are not well understood. …
(VL) are known to relapse; however, the risk factors for relapse are not well understood. …
[HTML][HTML] Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India
Background Visceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal
disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL …
disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL …
HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination
Although human immunodeficiency virus (HIV) and visceral leishmaniasis coinfection is
recognized as a major public health challenge in Africa, data regarding the prevalence in India …
recognized as a major public health challenge in Africa, data regarding the prevalence in India …
AmBisome monotherapy and combination AmBisome–miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human …
S Burza, R Mahajan, S Kazmi… - Clinical Infectious …, 2022 - academic.oup.com
Background Visceral leishmaniasis (VL) in patients with human immunodeficiency virus (HIV)
presents an increasingly important patient cohort in areas where both infections are …
presents an increasingly important patient cohort in areas where both infections are …
